Mitral atresia is a rare congenital heart defect in which the mitral valve is either absent or its anatomical structures are significantly underdeveloped, which leads to disruption of normal blood circulation between the left atrium and left ventricle of the heart. Normally, the mitral valve ensures a unidirectional flow of blood, allowing it to move from the atrium to the ventricle and preventing its backflow during ventricular contraction. Mitral atresia is usually accompanied by significant hemodynamic impairment, which requires early diagnostic and therapeutic intervention.
History of the disease and interesting historical facts
Mitral atresia, as one of the forms of heart defect, was first described in medical texts of the 20th century. In the 1930s, Dr. L. F. Badzhelidze paid special attention to mobile methods of analyzing the occurrence of congenital heart defects. In subsequent studies, key features of the clinical picture of this disease were determined, which made it possible to create a basis for more accurate diagnosis and presentation of surgical techniques in treatment. Given the rarity of this defect, compared to other heart anomalies, the history of its study and treatment remains less rich; however, the fundamental works on this topic formed the basis of the modern surgical and therapeutic approach.
Epidemiology
According to modern epidemiological studies, mitral valve atresia occurs with a frequency of about 1 in 30,000 newborns. Previously conducted studies recorded the prevalence of this defect at the level of 0.2-0.3% of the total number of congenital heart defects. Based on gender differences, it has been confirmed that this disease is more often diagnosed in women, which may be associated with certain genetic and chromosomal abnormalities.
Genetic predisposition to this disease
Mitral atresia may have a genetic predisposition associated with abnormalities in chromosomes 13 and 18, as well as mutations in genes responsible for the formation of the cardiovascular system. Studies show that mutations in the NKX2-5 family of genes, as well as in the GATA4 and TBX5 genes, may be associated with the development of heart defects, including mitral atresia. There are also studies confirming the presence of associations between mitral atresia and syndromes such as Down syndrome.
Risk factors for the development of this disease
Risk factors that contribute to the development of mitral valve atresia include:
- Environmental factors such as exposure to toxins, viral infections (eg, rubella) during pregnancy.
- Chemicals such as some drugs that are teratogens (eg, isotretinoin).
- A family history of cardiovascular disease that may increase the risk of heart defects in offspring.
- Some maternal endocrine diseases, such as diabetes or hypothyroidism, can affect fetal development.
Diagnosis of this disease
Various methods are used to diagnose mitral valve atresia:
- The main symptoms include shortness of breath, cyanosis, irregular heartbeat and decreased physical activity.
- Laboratory tests may include a complete blood count, electrolytes, and a blood pH test.
- Radiological tests such as chest x-rays can help detect changes in the heart shadow and lungs.
- Cardiac ultrasound (echocardiography) remains the gold standard for visualizing the anatomy and functionality of the heart.
- One of the tasks of differential diagnosis is to exclude other congenital heart defects, such as coarctation of the aorta or other valve closure anomalies.
Treatment
Treatment of mitral valve atresia is complex and includes:
- General treatment is aimed at stabilizing hemodynamics and eliminating heart failure. This may include the use of oxygen and other supportive therapies.
- Pharmacological treatment may include diuretics to reduce swelling and improve heart function.
- Surgical treatment involves the creation of anastomoses (eg, Blalac operation) to ensure adequate blood supply.
- Other treatments include the use of pacemakers, and in severe cases, a heart transplant may be recommended.
List of medications used to treat this disease
The following classes of drugs are used in the treatment of mitral valve atresia:
- Diuretics (eg, furosemide) to control swelling.
- ACE inhibitors (eg, enalapril) to reduce the workload on the heart.
- Beta blockers to control heart rhythm.
- Anticoagulants to prevent blood clots.
- Glycosides (eg, digoxin) to improve myocardial contractility.
Disease monitoring
Monitoring of patients with mitral atresia includes regular examinations by a cardiologist and the use of echocardiography to assess changes in the heart. The prognosis depends on the severity of the disease and the time of treatment. Patients who have had successful surgery may have a more optimistic prognosis, with good long-term results. Possible complications include heart failure, arrhythmias, and reoperations.
Age-related features of the disease
Mitral atresia can present differently depending on the age of the patient. In newborns, the condition is often diagnosed due to shortness of breath and cyanosis, requiring immediate emergency surgery. In older children, symptoms may gradually progress, slowly leading to heart failure. In adults who have undergone corrective surgery, there is a possibility of complications that require further monitoring.
Questions and Answers
- What are the main symptoms of mitral valve atresia? Major symptoms include shortness of breath, increasing fatigue, cyanosis, irregular heartbeat, and possible failure to gain normal weight in newborns.
- How is mitral valve atresia diagnosed? Diagnosis is made using echocardiography, chest X-ray and laboratory tests to assess the patient's condition.
- What treatment is recommended for patients with mitral valve atresia? Treatment may include drug therapy, surgery, anastomosis, and other methods, depending on the patient's condition.
- What is the prognosis for patients after surgery? The prognosis can be positive, especially with early diagnosis and successful surgical treatment, but complications remain a lifelong possibility.
- What is the role of genetics in the development of mitral valve atresia? Genetic factors can have a significant influence on the development of heart defects, including mutations in certain genes associated with the cardiovascular system.
